In this episode, hosts Kyle Kruse and Richard Meiklejohn are joined by Doug Evans, CEO of Lungpacer, to discuss innovative breakthroughs in respiratory care. Doug outlines the critical issue of mechanical ventilation, which affects 2 million patients annually in the U.S., with a 40% mortality rate among them. He provides detailed insights into how Lungpacer's neurostimulation technology aims to improve patient outcomes by maintaining diaphragm muscle function, thereby reducing time on ventilators and minimizing the need for reintubation. The discussion covers the rigorous research and FDA approval process, as well as the forthcoming Aero Nova system designed to assist patients from the onset of mechanical ventilation. Doug also shares the company's plans for commercialization, manufacturing scale-up, and future clinical milestones. The conversation highlights the potential impact of Lungpacer’s technology on patient survival rates and healthcare costs, positioning it as a transformative solution in critical care, a story sure to leave you informed and inspired.

Join us on this episode as we delve into a "silent epidemic" affecting millions: meniscus root tears, a leading cause of knee arthritis. Our guest, Dr. Chris Anderson, founding surgeon and Chief Medical Officer of Native Orthopedics, reveals the hidden prevalence of this debilitating injury, explaining how it impacts over 800,000 Americans annually and the critical need for a new approach to knee preservation. This episode uncovers why this problem has been historically overlooked and the limitations of traditional repair methods.Discover how Native Orthopedics is revolutionizing soft tissue repair with their FDA breakthrough-designated "Dragonfly" device. Dr. Anderson shares the ingenious, "finger trap" mechanism behind this knotless and adjustable solution, designed by a surgeon for surgeons. Learn how this innovation simplifies complex procedures, improves biomechanical repair, and is poised to introduce a new era of light-touch surgical solutions across sports medicine and beyond, promising better outcomes and faster recovery for patients. A fishing inspired tale that is sure to leave you informed and inspired.

In this episode of the MedTech Impact Podcast, Charles Gellman, CEO and Co-Founder of HiDo Health, discusses the company's mission to eliminate medication errors in the home. Gelman introduces their AI robotic caregiver, a system designed to ensure patients take the right medication at the right time. Unlike existing medication adherence solutions that rely on patient self-reporting or simple reminders, HiDo Health's technology automates the process, knows the medication name, dosage, frequency, and count, and even records consumption. This approach aims to stabilize chronic disease, reduce hospitalizations, and improve the overall quality of care.Charles emphasizes that the device was designed with significant patient input, focusing on accountability and caregiver needs. The system uses existing pill bottles with a special cap containing an RFID chip, and incorporates face ID and video recording to confirm medication intake. This technology integrates data for both patients and providers, and early results show a substantial reduction in hospitalizations and cost savings. HiDo Health is partnering directly with payers to get the device to patients, and is focused on expanding awareness of the technology, so be sure to tune in, so you can be informed and inspired.

This episode features Yashar Seyed Vahedein, CEO and Co-founder of Coredio, a company tackling the significant problem of heart failure management. Yashar outlines the immense global and US prevalence of heart failure, the high rates of readmission due to inadequate post-discharge monitoring, and the substantial financial burden this places on hospitals and payers. He highlights the limitations of current standard care (blood pressure cuffs and scales) in providing timely and accurate cardiac insights, contrasting them with the invasiveness and cost of solutions like catheterization and implantable devices.Coredio's innovative solution is a software platform that leverages existing wearable devices (like smartwatches and blood pressure cuffs) and patented AI and physics-based technology to extract key cardiac metrics comparable to those obtained through invasive procedures. This non-invasive approach aims to improve guideline-directed medication therapy adherence, reduce hospital readmissions and length of stay, and ultimately enhance patient outcomes by providing clinicians with timely data and enabling proactive intervention – all without requiring new devices for patients or hospitals. Tune in to learn more about this exciting startup so you can be informed and inspired.

In this episode, hosts Kyle Kruse and Richard Meiklejohn, interview Joseph ‘Yossi’ Mossel, CEO and Co-founder of Ibex Medical Analytics, about the company's innovative use of AI in cancer diagnostics. Yossi discusses the critical problem of diagnostic errors in pathology, which can reach up to 10% in some labs, and the growing shortage of pathologists worldwide. Ibex's AI technology acts as a "digital assistant" to pathologists, pre-analyzing cases and highlighting areas of concern, thereby increasing accuracy and efficiency.Yossi emphasizes that Ibex's AI is designed to augment, not replace, pathologists, allowing them to focus on complex cases while ensuring accuracy in routine diagnoses. The conversation touches on all the incredible data and partner foundations that been developed, which has led to significant deployments in Europe and the United States. Tune in to learn more about how Ibex is re-shaping pathology so you can be informed and inspired.

In this episode, we sit down with Dr. Nicholas Nikolov, Chief Medical Officer of Cellsound Aesthetics, to discuss a revolutionary approach to aesthetic treatments. Dr. Nikolov, a plastic surgeon, shares his journey from traditional invasive procedures to pioneering non-invasive solutions using non-focused ultrasound technology. Cellsound Aesthetics aims to rejuvenate tissue, improve blood flow, and contour the body without causing trauma or downtime. Dr. Nikolov details how the technology, originally developed for wound healing, has evolved to address various aesthetic concerns, offering patients a comfortable and effective alternative to traditional methods.Dr. Nikolov explains the science behind Cellsound, highlighting its unique ability to penetrate deep tissue layers and stimulate cellular activity without causing injury. He emphasizes the importance of patient comfort and the positive impact of the technology on their overall well-being. The conversation also delves into the company's go-to-market strategy, clinical study results, and the comprehensive training and support provided to practitioners. Dr. Nikolov's passion for the technology and its potential to transform the aesthetic industry is evident, making this episode one sure to leave you informed and inspired.

This episode features Prathamesh Prabhudasai, co-founder and CEO of SafeBVM, discussing the critical issue of ineffective manual ventilation during resuscitation. We uncover the alarming statistic that up to 50% of patients experience hypoxia due to improper bag-valve mask (BVM) use. SafeBVM addresses this problem with a novel device that works with any commercially available BVM, providing a flow-limiting valve to ensure safer and more effective breaths. Prath also emphasizes the challenges faced by healthcare providers due to infrequent BVM use and high staff turnover, and how SafeBVM's technology helps maintain competency and improve patient outcomes.SafeBVM's approach offers a comprehensive solution that includes training coupled with their optimized manual bag for ventilation. Prath touches on the importance of federal funding in supporting clinical trials and supporting their development journey. Thanks to this foundation, the company has already seen significant success in cities like Colorado Springs and Saint Charles, with positive clinical outcomes and growing adoption. The company is now focusing on scaling, while also preparing to release exciting clinical trial data, be sure to tune in so you can be informed and inspired.

This episode features Orahn Preiss-Bloom, Chief Innovation Officer of OSSIO, discussing the company's revolutionary tech that promotes natural healing in bones. OSSIO is tackling the long-standing issues associated with metal implants in orthopedic surgery, which often lead to complications like hardware removal surgeries, patient pain, and increased healthcare costs. Orahn explains how their OSSIOfiber product, a composite material made of biocompatible mineral fibers, provides the necessary strength for bone fixation while allowing the body to naturally remodel it into bone over time, eliminating the need for future hardware removal. The conversation delves into the challenges of bringing novel medical technologies to market, the importance of focusing on procedure-specific solutions, and the intricacies of building a successful go-to-market strategy in the orthopedic space. Orahn shines a light on how the market is shifting towards procedure ownership, where companies provide comprehensive solutions rather than just individual tools. Packed with insights into navigating the regulatory landscape, building a strong commercial team, and optimizing distribution strategies, this conversation will definitely leave you informed and inspired.

This episode features Ben Merewitz, CEO and Co-founder of Agile Devices. Ben discusses the challenges faced by interventional radiologists when navigating complex anatomy with traditional microcatheters, such as difficulties in maneuvering through tortuous vessels and achieving precise target placement. Agile Devices has developed a novel, microcatheter with active tip control, called Angler, that overcomes these limitations by allowing real-time control of the tip's shape, enabling physicians to navigate complex anatomy with greater ease and precision.The company has received FDA clearance for the Angler and is currently conducting limited releases to gather further clinical data and demonstrate the device's effectiveness in various interventional procedures, including embolization, neurovascular interventions, and more. Ben highlights the importance of the Boston area's vibrant medical device ecosystem in the development of this innovative technology and discusses the company's future plans, including expanding into new markets and developing new applications for their deflectable technology platform. With an ‘agile’ approach, Ben’s story is sure to keep you informed and inspired.

This episode features Andrew Goldsmith, Medical Director of UltraSight, and Ramya Singh, Chief Commercial Officer. They discuss the challenges of limited access to echocardiography due to a shortage of cardiac sonographers and the resulting delays in patient care. UltraSight addresses this by developing AI-powered software that guides clinicians in acquiring high-quality echocardiograms using standard ultrasound devices. This technology enhances the accessibility of ultrasound technology by enabling a wider range of healthcare professionals to perform these critical examinations. The company focuses on improving patient outcomes by enabling faster diagnoses, reducing wait times, and improving the efficiency of healthcare delivery. UltraSight's Go-to-Market strategy targets key areas; hospitals, clinics, and home healthcare settings, aiming to integrate their solution into existing workflows and improve patient care across various settings. The company emphasizes the importance of user-friendliness, ease of implementation, and a focus on patient safety and improved outcomes. With the company primed to make real impact, tune in so you can be informed and inspired.

This episode features Evan Ruff, CEO and Co-founder of Oxos Medical. Oxos Medical is developing innovative portable X-ray devices designed to revolutionize healthcare by bringing imaging to the point of need. Recognizing the limitations of traditional X-ray systems, which are often bulky, expensive, and require specialized infrastructure, Oxos Medical has created a compact and user-friendly device that can be easily used in various settings, from emergency departments and clinics to sports fields and even remote locations.Evan delves into the challenges of accessing traditional X-ray technology, including limited availability, high costs, and the need for specialized personnel. We discuss how Oxos Medical's portable X-ray device addresses these challenges by improving accessibility, enhancing workflow efficiency, and empowering clinicians with greater autonomy. The conversation also explores the potential of AI integration, such as AI-powered image analysis for improved diagnostic accuracy and streamlined workflows. With a strong sales pipeline in place, the OXOS team is primed to make an impact, tune in so you can be informed and inspired.

In this episode, Spencer Jones, Founder of XO Medtech, discusses the problem with innovation silos in medical technology and the commercialization process. Spencer highlights how innovators are often afraid to share information about what they are working on, and this can stifle progression. Additionally, there is a lack of access to open networks for comprehensive practical knowledge transfer related to commercialization.Spencer outlines how XO Medtech’s platform offers a new online community approach for educating and connecting innovators, helping provide them with the resources needed to succeed. This includes a community forum, educational content, and a range of free templates. As well as aiding knowledge transfer, an additional platform, Medtech Vendors, will help improve the process of finding the right suppliers. With community and value-driven connections at the heart of all they do, this is definitely a conversation to keep you informed and inspired.Here are the key takeaways:* Siloed nature of Medtech and Medtech innovation: Startup resources are often constrained by location and network which can hinder innovation.* Limited access to specialized networking & knowledge training: Medtech innovators often have difficulty finding accessible resources and support they need to succeed.* Importance of building a community: XO Medtech is building a community of Medtech innovators to help them connect with each other and share resources.* Focus on actionable content: The platform provides innovators with access to practical tools and templates to help them advance their businesses.* Standardization of processes: A new Medtech Vendors platform will help standardize the procurement process in the Medtech industry to improve efficiency.

In this episode, Swarna Shiv, CEO and founder of Unsmudgeable, delves into the challenges of smudged eyewear and how her company is revolutionizing lens technology. Unsmudgeable aims to eliminate the safety and productivity issues caused by smudged glasses, a huge problem that affects millions of people globally. Swarna shares insights into how the company started, the unique technology behind their coatings, and the journey from idea to patent-pending innovation.Unsmudgeable's focus for 2025 is commercialization and they are actively working with lens manufacturers to apply this technology to various surfaces. Swarna explains their strategy for scaling up through equity crowdfunding and emphasizes the importance of sustainability in their product development. Tune in to be informed and inspired.

The episode discusses preventative care, specifically how virtual care can help people with chronic conditions manage their health and avoid hospitalization. David Dlesk, CEO and Co-Founder of Embrace Prevention Care, shares an overview of the challenges of preventative care in the current healthcare system and how Embrace helps patients with chronic conditions, like dementia, take action to improve their health.Embrace uses virtual consultations with nurse practitioners to provide ongoing support and coaching to patients. This helps patients make the lifestyle changes necessary to slow the progression of their chronic conditions. The Centers for Medicare & Medicaid (CMS) has created a new program, GUIDE, to specifically target dementia patients and caregivers. Embrace is one of the select organizations chosen to provide this program.The key takeaways from the podcast episode are:* Preventative care is not currently well- incentivized in the healthcare system, but it is critical for managing chronic conditions.* Virtual care can be an effective way to deliver preventative care.* CMS has created a new program, GUIDE, to provide virtual preventative care to dementia patients and caregivers.* Embrace is a company that is using virtual care to help people with chronic conditions manage their health and avoid hospitalization.

This episode features Ben Holmes, CEO and Co-founder of Nanochon, a medical device company focused on revolutionizing cartilage repair. The discussion highlights the significant challenges faced by patients with cartilage damage, including limited treatment options and the potential for further joint degeneration.Nanochon is developing a groundbreaking 3D-printed implant designed to mimic the natural structure and function of cartilage. This innovative device is designed to be minimally invasive and easily implanted, offering a potential solution for patients facing cartilage damage and potentially delaying or even preventing the need for knee replacement surgery.Ben shares insights into Nanochon's development progress, including upcoming human trials and their recent move to LaunchPort in Baltimore, a unique incubator space that provides access to state-of-the-art manufacturing facilities for medtech startups. With team expansion plans on the horizon, this story is fueled with insights, sure to leave you informed and inspired.

This episode discusses a huge unmet need in the medical device space: treatment for mixed urinary incontinence. Millions of patients, primarily women, suffer from this condition, and there is no effective treatment on the market. Current treatment options leave care gaps and patients resorting to over-the-counter products for symptom management.Juniper Biomedical is a company that is developing a new type of treatment for mixed urinary incontinence. They are developing a unique neuromodulation micro implant that can be implanted with a minimally invasive procedure to deliver a very precise therapy. This has the potential to solve the problems of mixed incontinence, eliminate issues with inaccurate diagnosis, and importantly, provide a solution that patients are more likely to accept.CEO and co-founder, David Constantine joins us to discuss their exciting progress, from extensive preclinical studies, to upcoming clinical trials. After a year of multiple highlights, including award winning on the stage of Medtech Innovator, the future looks bright for Juniper Biomedical. Their technology has the potential to make a real difference in the lives of millions of patients with pelvic health conditions, a story sure to leave you, informed and inspired.

This episode features Dave Rosa, CEO of NeuroOne, a company leading the way in innovative solutions for various neurological disorders. The discussion highlights the significant challenges faced by patients with epilepsy, particularly those whose condition is resistant to medication. Traditional treatment often involves multiple invasive surgeries, placing a significant physical and emotional burden on patients.NeuroOne has developed a groundbreaking technology that integrates both diagnostic and therapeutic functions into a single device. This innovative approach enables physicians to identify the source of seizures and then immediately proceed with ablation of the affected brain tissue within a single surgical procedure, minimizing patient discomfort and hospital stays. We explore the strategic partnership with Zimmer Biomet that has been pivotal for NeuroOne's successful market access, helping accelerate commercialization. With additional data insights, and future pharma collaboration opportunities, the future is truly bright for Dave and the team. NeuroOne is helping advance the movement towards personalized medicine, offering hope for improved patient outcomes, a story sure to leave you informed and inspired.

Novosound is a pioneering company in the field of ultrasound technology, with a mission to revolutionize the way we monitor vital signs. Traditional blood pressure monitoring methods, often involving bulky cuffs and infrequent measurements, can be inconvenient and provide limited insights. Novosound aims to address these limitations through their innovative, non-invasive, and continuous blood pressure monitoring solution.By leveraging advanced thin-film ultrasound technology, Novosound's sensors can be integrated into wearable devices, making it possible to track blood pressure in real-time. This continuous monitoring can provide valuable information to both patients and healthcare providers, enabling early detection of potential health issues and more effective management of conditions like hypertension.In this episode, we delve deeper into the technology behind Novosound's innovations. Dave Hughes, CEO and founder of Novosound, discusses the academic research foundation of the technology, along with the exciting potential for partners to leverage new capabilities with their wearable application. Dave details the company's strategy for a future where continuous, non-invasive monitoring becomes the norm, a story sure to leave you informed and inspired.

IntelVasc is a medical technology company focused on addressing the significant issue of peripheral arterial disease (PAD). This condition, often undiagnosed, can lead to serious complications like heart attacks and strokes. CEO & co-founder, Andrew Ortega-Verdaguer, joins this episode to discuss how he plans to lead the business from visionary prototype through to market as the team gears up for first FDA discussions early next year.The company's innovative solution involves a minimally invasive sensor, inserted subcutaneously near to the femoral artery. This sensor, paired with a portable scanner, will enable patients to monitor their vascular health at home. By collecting real-time data on blood flow, the technology can empower patients and clinicians to proactively identify potential issues and intervene early, reducing the risk of major complications.IntelVasc's technology has the potential to revolutionize the management of PAD. By providing a convenient and reliable method for monitoring vascular health, the company aims to improve patient outcomes, reduce healthcare costs, and enhance the overall quality of life for individuals with this condition. With additional AI and ML opportunities, this is an exciting medtech story sure to keep you informed and inspired.

Epilepsy is a neurological disorder affecting millions worldwide, significantly impacting the quality of life of both patients and their loved ones. Traditional management usually relies heavily on medication, which can have severe side effects. Despite the high prevalence of the condition, there is still a lack of objective data on seizure activity.EpiWatch CEO, Teresa Prego, joins this episode to discuss their wearable device designed to detect and alert for tonic-clonic seizures. By leveraging Apple Watch technology, EpiWatch provides real-time seizure detection and can alert caregivers, potentially reducing the risk of injury and improving response times. The device also collects valuable data on seizure patterns, enabling clinicians to make more informed treatment decisions.By partnering with clinicians, pharmaceutical companies, and device manufacturers, EpiWatch can integrate seamlessly with existing healthcare solutions, helping contribute to a broader ecosystem of epilepsy management. With FDA clearance anticipated in 2025, EpiWatch has the potential to revolutionize the way epilepsy is managed, improving the lives of patients and their families, a mission sure to leave you informed and inspired.